Ryan R. Willard

2.5k total citations
18 papers, 815 citations indexed

About

Ryan R. Willard is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Ryan R. Willard has authored 18 papers receiving a total of 815 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 14 papers in Pulmonary and Respiratory Medicine and 8 papers in Oncology. Recurrent topics in Ryan R. Willard's work include Protein Degradation and Inhibitors (15 papers), Prostate Cancer Treatment and Research (12 papers) and Ubiquitin and proteasome pathways (7 papers). Ryan R. Willard is often cited by papers focused on Protein Degradation and Inhibitors (15 papers), Prostate Cancer Treatment and Research (12 papers) and Ubiquitin and proteasome pathways (7 papers). Ryan R. Willard collaborates with scholars based in United States. Ryan R. Willard's co-authors include Andrew P. Crew, Craig M. Crews, Taavi K. Neklesa, Hanqing Dong, Jing Wang, John Houston, I Taylor, Jennifer Pizzano, Mark Bookbinder and Meizhong Jin and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Molecular Cancer Therapeutics.

In The Last Decade

Ryan R. Willard

17 papers receiving 797 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ryan R. Willard United States 11 712 349 218 140 59 18 815
Vijaya L. Dommeti United States 5 821 1.2× 161 0.5× 214 1.0× 429 3.1× 69 1.2× 8 1.0k
Weiguo Xiang United States 7 743 1.0× 336 1.0× 235 1.1× 141 1.0× 32 0.5× 16 846
S H Lee South Korea 7 344 0.5× 135 0.4× 96 0.4× 54 0.4× 28 0.5× 8 516
Arnold Bolomsky Austria 12 450 0.6× 200 0.6× 312 1.4× 23 0.2× 14 0.2× 31 603
Jennifer Gauvin United States 9 352 0.5× 141 0.4× 126 0.6× 99 0.7× 7 0.1× 11 529
John Houston United States 8 437 0.6× 233 0.7× 136 0.6× 66 0.5× 34 0.6× 12 487
Sainan An China 6 402 0.6× 198 0.6× 81 0.4× 54 0.4× 16 0.3× 7 518
Heung Kyoung Lee South Korea 13 235 0.3× 178 0.5× 56 0.3× 82 0.6× 19 0.3× 18 391
Katie Kane United Kingdom 6 363 0.5× 256 0.7× 19 0.1× 101 0.7× 10 0.2× 9 531
Yasunobu Kuraishi Japan 9 240 0.3× 138 0.4× 38 0.2× 68 0.5× 18 0.3× 16 429

Countries citing papers authored by Ryan R. Willard

Since Specialization
Citations

This map shows the geographic impact of Ryan R. Willard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryan R. Willard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryan R. Willard more than expected).

Fields of papers citing papers by Ryan R. Willard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryan R. Willard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryan R. Willard. The network helps show where Ryan R. Willard may publish in the future.

Co-authorship network of co-authors of Ryan R. Willard

This figure shows the co-authorship network connecting the top 25 collaborators of Ryan R. Willard. A scholar is included among the top collaborators of Ryan R. Willard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryan R. Willard. Ryan R. Willard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Cheng, Jonathan, et al.. (2024). The Elekta Esteya® electronic brachytherapy system in non-melanoma skin cancers: A post-market observational study. Journal of Contemporary Brachytherapy. 16(6). 478–488.
2.
Snyder, Lawrence B., Taavi K. Neklesa, Ryan R. Willard, et al.. (2024). Preclinical Evaluation of Bavdegalutamide (ARV-110), a Novel PROteolysis TArgeting Chimera Androgen Receptor Degrader. Molecular Cancer Therapeutics. 24(4). 511–522. 24 indexed citations
3.
Snyder, Larry, Taavi K. Neklesa, Xin Chen, et al.. (2023). Abstract ND03: Discovery of ARV-766, an androgen receptor degrading PROTAC® for the treatment of men with metastatic castration resistant prostate cancer. Cancer Research. 83(7_Supplement). ND03–ND03. 12 indexed citations
4.
Snyder, Lawrence B., John J. Flanagan, Yimin Qian, et al.. (2021). Abstract 44: The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer. Cancer Research. 81(13_Supplement). 44–44. 74 indexed citations
5.
Snyder, Lawrence B., Taavi K. Neklesa, Xin Chen, et al.. (2021). Abstract 43: Discovery of ARV-110, a first in class androgen receptor degrading PROTAC for the treatment of men with metastatic castration resistant prostate cancer. Cancer Research. 81(13_Supplement). 43–43. 49 indexed citations
6.
Neklesa, Taavi K., Lawrence B. Snyder, Ryan R. Willard, et al.. (2019). ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer.. Journal of Clinical Oncology. 37(7_suppl). 259–259. 153 indexed citations
7.
Qian, Yimin, Monica Andreoli, Mark Bookbinder, et al.. (2019). Abstract P5-04-18: ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer. Cancer Research. 79(4_Supplement). P5–4. 106 indexed citations
8.
Alabi, Shanique, Ryan R. Willard, Jing Wang, et al.. (2018). Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance. Communications Biology. 1(1). 100–100. 273 indexed citations
9.
Neklesa, Taavi K., Lawrence B. Snyder, Ryan R. Willard, et al.. (2018). An oral androgen receptor PROTAC degrader for prostate cancer.. Journal of Clinical Oncology. 36(6_suppl). 381–381. 14 indexed citations
10.
Qian, Yimin, Monica Andreoli, Mark Bookbinder, et al.. (2018). Abstract P4-04-04: Identification and development of oral estrogen receptor PROTAC degraders for breast cancer. Cancer Research. 78(4_Supplement). P4–4. 2 indexed citations
11.
Neklesa, Taavi K., Lawrence B. Snyder, Ryan R. Willard, et al.. (2018). Abstract 5236: ARV-110: An androgen receptor PROTAC degrader for prostate cancer. Cancer Research. 78(13_Supplement). 5236–5236. 50 indexed citations
12.
Neklesa, Taavi K., Lawrence B. Snyder, Mark Bookbinder, et al.. (2017). An oral androgen receptor PROTAC degrader for prostate cancer.. Journal of Clinical Oncology. 35(6_suppl). 273–273. 23 indexed citations
13.
Neklesa, Taavi K., Lawrence B. Snyder, Mark Bookbinder, et al.. (2017). Abstract 5637: An oral Androgen Receptor PROTAC degrader for prostate cancer. Cancer Research. 77(13_Supplement). 5637–5637. 2 indexed citations
14.
Neklesa, Taavi K., Meizhong Jin, Andrew P. Crew, et al.. (2016). ARV-330: Androgen receptor PROTAC degrader for prostate cancer.. Journal of Clinical Oncology. 34(2_suppl). 267–267. 11 indexed citations
15.
Winkler, James D., Meizhong Jin, Ryan R. Willard, et al.. (2015). Abstract PR08: ARV-330: An androgen receptor PROTAC degrader for prostate cancer. Molecular Cancer Therapeutics. 14(12_Supplement_2). PR08–PR08. 1 indexed citations
16.
Jin, Meizhong, James D. Winkler, Kevin Coleman, et al.. (2015). Abstract LB-097: Targeted degradation of the androgen receptor in prostate cancer. Cancer Research. 75(15_Supplement). LB–97. 1 indexed citations
17.
Talbot, Neil C., Thomas J. Caperna, Ryan R. Willard, John Meekin, & Wesley M. Garrett. (2010). Characterization of Two Subpopulations of the PICM-19 Porcine Liver Stem Cell Line for use in Cell-Based Extracorporeal Liver Assistance Devices. The International Journal of Artificial Organs. 33(6). 348–361. 10 indexed citations
18.
Willard, Ryan R., Nancy W. Shappell, John Meekin, Neil C. Talbot, & Thomas J. Caperna. (2009). Cytochrome P450 expression profile of the PICM-19H pig liver cell line: potential application to rapid liver toxicity assays. In Vitro Cellular & Developmental Biology - Animal. 46(1). 11–19. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vijaya L. Dommeti Breakdown of academic impact, for papers by Weiguo Xiang Breakdown of academic impact, for papers by S H Lee Breakdown of academic impact, for papers by Arnold Bolomsky Breakdown of academic impact, for papers by Jennifer Gauvin Breakdown of academic impact, for papers by John Houston Breakdown of academic impact, for papers by Sainan An Breakdown of academic impact, for papers by Heung Kyoung Lee Breakdown of academic impact, for papers by Katie Kane Breakdown of academic impact, for papers by Yasunobu Kuraishi
Rankless by CCL
2026